Esperion Therapeutics Inc.
ESPR
Market Cap$231.89M
Close$
$11.14
851.8% upside
Current Fair Value
851.8% upsideUndervalued by 851.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $231.89 Million |
|---|---|
| Enterprise Value | $491.58 Million |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.28 |
| Beta | 0.65 |
| Outstanding Shares | 196,127,948 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.5 |
|---|---|
| PEG | 0.9 |
| Price to Sales | 1.17 |
| Price to Book Ratio | -0.39 |
| Enterprise Value to Revenue | 1.89 |
| Enterprise Value to EBIT | -12.49 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.76 |
| Debt to Equity | -0.88 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben